TriangleAnti-CD40 Agonist Monoclonal… (NCT06980038)
Anti-CD40 Agonist Monoclonal Antibody CDX-1140 trial for Head and Neck Squamous Cell Carcinoma (NCT06980038). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with surgically removable stage III–IV head-and-neck squamous cancer without distant spread. Oropharyngeal tumors must be p16-negative; prior PD-1/PD-L1 treatment is excluded.
The idea: compare cemiplimab alone with CDX-1140 plus cemiplimab before surgery. CDX-1140 activates CD40 signaling in immune cells; cemiplimab blocks PD-1. Infusions precede surgery on days 29–36. Tumor biopsies are required.
This phase 2 study plans 44 patients. Matin Imanguli leads the NCI-sponsored trial, with 12 recruiting US sites. Both newly diagnosed and recurrent cancers can qualify.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.